MXPA05011432A - Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. - Google Patents
Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.Info
- Publication number
- MXPA05011432A MXPA05011432A MXPA05011432A MXPA05011432A MXPA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A
- Authority
- MX
- Mexico
- Prior art keywords
- thrombin
- mopidamole
- treatment
- dipyridamole
- disorders caused
- Prior art date
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002768 dipyridamole Drugs 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 108090000190 Thrombin Proteins 0.000 title abstract 2
- 102000003790 Thrombin receptors Human genes 0.000 title abstract 2
- 108090000166 Thrombin receptors Proteins 0.000 title abstract 2
- 208000001435 Thromboembolism Diseases 0.000 title abstract 2
- 229960004072 thrombin Drugs 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46516803P | 2003-04-24 | 2003-04-24 | |
| PCT/EP2004/004097 WO2004093881A2 (en) | 2003-04-24 | 2004-04-17 | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05011432A true MXPA05011432A (es) | 2006-03-21 |
Family
ID=33311001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05011432A MXPA05011432A (es) | 2003-04-24 | 2004-04-17 | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. |
Country Status (12)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| AU2005245271A1 (en) | 2004-05-13 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Use of dipyridamole for treatment of resistance to platelet inhibitors |
| JP2008517974A (ja) * | 2004-10-25 | 2008-05-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| DE102005028168B3 (de) | 2005-06-17 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung |
| CA2657269A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors |
| CA2657270A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New paediatric indications for direct thrombin inhibitors |
| JP2009543842A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管分野における直接トロンビン阻害薬のための新規適応 |
| WO2009080301A1 (en) * | 2007-12-21 | 2009-07-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke |
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| JP2012500244A (ja) * | 2008-08-19 | 2012-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍療法におけるダビガトラン |
| BRPI0921353A2 (pt) * | 2008-11-11 | 2015-12-29 | Boehringer Ingelheim Int | método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com eficácia aperfeiçoada com relação á terapia com warfarina convencional. |
| WO2011085473A1 (en) * | 2010-01-13 | 2011-07-21 | Linda Penn | Treating cancer with statins and compounds having dipyridamole activity |
| AU2016337564A1 (en) * | 2015-10-15 | 2018-05-31 | Drug Rediscovery Group Ltd | Low dose oral dipyridamole compositions and uses thereof |
| US12606797B2 (en) * | 2018-06-15 | 2026-04-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of detection of mechanically-activated platelet activation and uses thereof |
| US20260060965A1 (en) * | 2024-08-26 | 2026-03-05 | Research Institute at Nationwide Children’s Hospital | Modulating the acute foreign body reaction to reduce stenosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| GB1051218A (cg-RX-API-DMAC10.html) | 1963-03-09 | |||
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3237575A1 (de) | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| DE4035961A1 (de) | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
| US20020048599A1 (en) | 2000-10-20 | 2002-04-25 | Thomas H. Mueller | Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation |
| HUP0304058A2 (hu) * | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| EP1250921A1 (en) | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
| EP1308179A1 (en) * | 2001-10-30 | 2003-05-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Improved endoprosthetic device |
| US20030180282A1 (en) * | 2002-03-25 | 2003-09-25 | Victor Serebruany | Method of treatment of thrombotic events |
| JP2006500365A (ja) * | 2002-08-14 | 2006-01-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ｐ３８ＭＡＰキナーゼインヒビターを用いた抗凝固及び線維素溶解療法 |
| JP2006516593A (ja) * | 2003-02-07 | 2006-07-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
-
2004
- 2004-04-17 WO PCT/EP2004/004097 patent/WO2004093881A2/en not_active Ceased
- 2004-04-17 RU RU2005136383/14A patent/RU2005136383A/ru not_active Application Discontinuation
- 2004-04-17 BR BRPI0409796-3A patent/BRPI0409796A/pt not_active IP Right Cessation
- 2004-04-17 CA CA002523157A patent/CA2523157A1/en not_active Abandoned
- 2004-04-17 MX MXPA05011432A patent/MXPA05011432A/es not_active Application Discontinuation
- 2004-04-17 JP JP2006505175A patent/JP2006524203A/ja active Pending
- 2004-04-17 EP EP04728114A patent/EP1622621A2/en not_active Withdrawn
- 2004-04-17 AU AU2004231306A patent/AU2004231306A1/en not_active Abandoned
- 2004-04-17 EP EP09152218A patent/EP2062580A1/en not_active Withdrawn
- 2004-04-17 KR KR1020057020187A patent/KR20060007034A/ko not_active Withdrawn
- 2004-04-17 CN CNA200480017862XA patent/CN1812792A/zh active Pending
- 2004-04-22 US US10/830,294 patent/US20050014770A1/en not_active Abandoned
-
2005
- 2005-10-04 ZA ZA200508016A patent/ZA200508016B/en unknown
-
2006
- 2006-09-01 US US11/469,503 patent/US20070105753A1/en not_active Abandoned
-
2009
- 2009-04-03 US US12/418,001 patent/US20090192123A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050014770A1 (en) | 2005-01-20 |
| CN1812792A (zh) | 2006-08-02 |
| US20070105753A1 (en) | 2007-05-10 |
| CA2523157A1 (en) | 2004-11-04 |
| WO2004093881A3 (en) | 2005-06-16 |
| EP2062580A1 (en) | 2009-05-27 |
| EP1622621A2 (en) | 2006-02-08 |
| BRPI0409796A (pt) | 2006-05-30 |
| KR20060007034A (ko) | 2006-01-23 |
| WO2004093881A2 (en) | 2004-11-04 |
| RU2005136383A (ru) | 2007-06-10 |
| US20090192123A1 (en) | 2009-07-30 |
| AU2004231306A1 (en) | 2004-11-04 |
| JP2006524203A (ja) | 2006-10-26 |
| ZA200508016B (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004093881A3 (en) | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | |
| TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| BR0107732A (pt) | Método para prevenir ou tratar uma doença | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| TN2009000137A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| WO2005051429A3 (en) | Targeted conjugates with a modified saccharide linker | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| IL128723A0 (en) | Pharmaceutical compositions containing rar antagonists and rxr agonists | |
| UA98462C2 (ru) | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| SE0400184D0 (sv) | New therapeutical use | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| TNSN07474A1 (en) | Dosage regimen for prasugrel | |
| ATE392901T1 (de) | Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| WO2004069254A3 (en) | Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders | |
| BRPI0410651A (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |